Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma

2017 ◽  
Author(s):  
Vassil Mihaylov
Keyword(s):  
Liver Transplantation ◽  
Epithelioid Hemangioendothelioma

scholarly journals Living-related liver transplant to treat epithelioid hemangioendothelioma – a case report

2005 ◽  
Vol 8 (4) ◽  
pp. 449-451
Author(s):  
Marcelo A. F. Ribeiro Jr ◽  
Christian Evangelista Garcia ◽  
Telma Eugênio dos Santos ◽  
Adavio de Oliveira e Silva ◽  
Regina Leitão ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Case Report ◽  
Liver Transplant ◽  
Soft Tissues ◽  
Liver Tumors ◽  
Epithelioid Hemangioendothelioma ◽  
Low Grade ◽  
Living Related Liver Transplant ◽  
Transplantation Technique ◽  
Living Related

Introduction: Epithelioid hemangioendothelioma of liver is a rare, low-grade neoplasm of vascular origin that has an unpredictable malignant potential. It preferentially arises in soft tissues and bones, and seldom in the liver. Biologically, it trends to be multi-focal and often unresectable. Objective: The outcome of a patient submitted to a living-related liver transplant to treat epithelioid hemangioendothelioma of the liver. Case report: The reported case involves a 39-year old female patient with an immense epithelioid hemangioendothelioma of the liver, involving segments III, IV, V, VII, and VIIl. The prognostic to any kind of treatment was considered unfavorable, and the decision of submitting her to a liver transplant was made. It was suggested a living-related liver transplant. The donor was the patient’s 36-year old brother, who donated his right liver lobe (segments V, VI, VII, VIII). The recipient´s original liver was large, presenting very solid consistence and no node evidence. The transplant itself was performed using the conventional living-related liver transplantation technique. The recovery was good, and she was discharged from hospital on the 15th postoperative day using micophenolate mofetil, tacrolimus, and corticoid. Conclusion: Liver transplantation for epithelioid hemangioendothelioma of the liver can be performed with acceptable survival rate. The living related liver transplant opens a great perspective to that group of patients presenting liver tumors and who are unfeasible to wait for an organ on a waiting list.

scholarly journals Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma: The Canadian Multicentre Experience

2008 ◽  
Vol 22 (10) ◽  
pp. 821-824 ◽  
Author(s):  
Carmine G Nudo ◽  
Eric M Yoshida ◽  
Vincent G Bain ◽  
Denis Marleau ◽  
Phil Wong ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Survival Rate ◽  
Liver Lesion ◽  
Epithelioid Hemangioendothelioma ◽  
Rare Entity ◽  
Rare Tumour ◽  
Time To Recurrence ◽  
The Mean ◽  
Mean Time

INTRODUCTION: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare entity. At the present time, there is no standardized effective therapy. Liver transplantation (LT) has emerged as a treatment for this rare tumour.OBJECTIVE: To evaluate the outcome of liver transplantation for HEHE at eight centres across Canada.METHODS: The charts of patients who were transplanted for HEHE at eight centres across Canada were reviewed.RESULTS: A total of 11 individuals (eight women and three men) received a LT for HEHE. All LTs were performed between 1991 and 2005. The mean (± SD) age at LT was 38.7±13 years. One patient had one large liver lesion (17 cm × 14 cm × 13 cm), one had three lesions, one had four lesions and eight had extensive (five or more) liver lesions. One patient had spleen involvement and two had involved lymph nodes at the time of transplantation. The mean duration of follow-up was 78±63 months (median 81 months). Four patients (36.4%) developed recurrence of HEHE with a mean time to recurrence of 25±25 months (median 15.6 months) following LT. The calculated survival rate following LT for HEHE was 82% at five years.CONCLUSIONS: The results of LT for HEHE are encouraging, with a recurrence rate of 36.4% and a five-year survival rate of 82%. Further studies are needed to help identify patients who would benefit most from LT for this rare tumour.

Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e21527-e21527
Author(s):  
G. Schilling ◽  
G. Schuch ◽  
J. P. Panse ◽  
M. Sterneck ◽  
C. Bokemeyer
Keyword(s):  
Liver Transplantation ◽  
Case Report ◽  
Stable Disease ◽  
Locally Advanced ◽  
Angiogenesis Inhibitors ◽  
Epithelioid Hemangioendothelioma ◽  
Extrahepatic Manifestations ◽  
First Case ◽  
Daily Dose ◽  
Higher Doses

e21527 Background: HEH is a rare tumor of the liver with an unpredictable malignant potential. Surgical resection or liver transplantation is recommended in locally advanced disease and has been successfully performed in selected cases with extrahepatic manifestations. Systemic therapy, however, is not standardized. Small cohorts have been treated with interferon, chemotherapy and angiogenesis inhibitors such as thalidomide with various results. Case report: A 33-year old caucasian previously healthy male was admitted to hospital with newly diagnosed suspicious lesions in liver and spleen. Further analyses showed additional pulmonal nodules. Biopsy revealed a tumor with predominant epithelioid cells, positive for CD31 and CD34 and negative for CD117, HHV8, AFP and CEA, classified as a HEH. Disease progressed during first line treatment with adriamycin and ifosfamide (2 cycles given). Based on a case report with encouraging results with thalidomide we treated our patient with lenalidomide, which is known to have less side effects while being more effective in the myeloma setting. After 6 courses of lenalidomide 25mg daily (21/28), regression of the splenic lesions was detected. Retrospective analysis after 9 cycles demonstrated stable disease in comparison to the recent investigation, but an overall progression of 22% according to RECIST criteria in the liver was observed. Due to the excellent tolerance we increased the daily dose to 30 mg (21/28) and 6 months later a slight regression in the lung and overall stable disease in the liver was observed. The splenic lesion disappeared completely. The patient was listed for liver transplantation and after another 4 months on lenalidomide 30 mg, he was successfully transplanted recently. Because of the remaining extrahepatic lesions it is planned to continue lenalidomide therapy in combination with the immunosuppressant rapamycine. Conclusions: We report the first case of successful therapy with lenalidomide in HEH. Higher doses than 25mg seem to be more effective. We grateful thank Celgene for offering us lenalidomide for this off label use. No significant financial relationships to disclose.

Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B

2002 ◽  
Vol 74 (1) ◽  
pp. 128-130 ◽  
Author(s):  
Liise K. Kayler ◽  
Robert M. Merion ◽  
Juan D. Arenas ◽  
John C. Magee ◽  
Darrell A. Campbell ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Interferon Alpha ◽  
Epithelioid Hemangioendothelioma ◽  
Interferon Alpha 2B
Sign in / Sign up

Export Citation Format

Share Document